In lung adenocarcinoma, GFPT2, but not GFPT1, correlates with poor clinical outcomes [39,40]; however, GFPT1 is required for glycosylation and high expression of GFPT1 predicts poor prognosis in pancreatic ductal adenocarcinoma [41]. This evidence concerns the gene GFPT1 and lung adenocarcinoma.